Insulet France insulin pump patent Medtrum TouchCare Nano
Left: a diagram of the Insulet insulin pump patent in question. Top right: The Insulet Omnipod 5. Bottom right: The Medtrum TouchCare Nano.

JUVE-Patent reports that the Judicial Court of Paris again ruled in favor of Insulet

(Nasdaq: PODD)

 in its patent battle with Medtrum.

According to the report, the court sided with Insulet in a case regarding the company’s patent (EP 1 874 390). The ruling finds that Medtrum’s A6 and A7+ TouchCare insulin pump devices infringe the valid Insulet patent.

However, JUVE-Patent says the judges found that Medtrum’s clinical trials for the A7+ device was responsible for the infringement. The outlet says this is a move “not before seen in French courts.” So, in this instance, Insulet won the patent spat before the infringing devices went commercial. The report says courts usually deliver these types of rulings once products hit the market.

This ruling follows another infringement declared by the Judicial Court of Paris last year.

Get the full story at our sister site, Drug Delivery Business News.